Monitoring disease response to tyrosine kinase inhibitor therapy in CML.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn , Issue , 2009, Pages 477-487

  Hughes, Timothy P ^a   Branford, Susan ^a  

^a Centre for Cancer Biology and Department of Haematology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; RNA; TUMOR PROTEIN;

BLOOD; BONE MARROW EXAMINATION; CHRONIC MYELOID LEUKEMIA; COMPUTER SYSTEM; DRUG ANTAGONISM; DRUG MONITORING; DRUG RESISTANCE; ENZYMOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; LEUKOCYTE COUNT; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; REMISSION; REVIEW;

ANTINEOPLASTIC AGENTS; BONE MARROW EXAMINATION; COMPUTER SYSTEMS; DNA MUTATIONAL ANALYSIS; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTE COUNT; MUTATION; NEOPLASM PROTEINS; PATIENT COMPLIANCE; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 77949442316     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2009.1.477     Document Type: Review

References (52)